Joshua L Wang1, Rolf F Barth2, Robert Cavaliere3, Vinay K Puduvalli3, Pierre Giglio3, Russell R Lonser1, J Bradley Elder1. 1. Department of Neurological Surgery, The Ohio State University College of Medicine Wexner Medical Center, Columbus, Ohio, United States of America. 2. Department of Pathology, The Ohio State University College of Medicine Wexner Medical Center, Columbus, Ohio, United States of America. 3. Division of Neuro-Oncology, Department of Neurology, The Ohio State University College of Medicine Wexner Medical Center, Columbus, Ohio, United States of America.
Abstract
BACKGROUND: Carboplatin is a potent cytoreductive agent for a variety of solid tumors. However, when delivered systemically, clinical efficacy for the treatment of high grade gliomas is poor due to limited penetration across the blood-brain barrier (BBB). Direct intracerebral (IC) convection-enhanced delivery (CED) of carboplatin has been used to bypass the BBB and successfully treat the F98 rat glioma. Based on these studies, we initiated a Phase I clinical trial. OBJECTIVE: This Phase I clinical trial was conducted to establish the maximum tolerated dose and define the toxicity profile of carboplatin delivered intracerebrally via convection enhanced delivery (CED) for patients with high grade glial neoplasms. METHODS: Cohorts of 3 patients with recurrent WHO grade III or IV gliomas were treated with escalating doses of CED carboplatin (1-4 μg in 54mL over 72 hours) delivered via catheters placed at the time of recurrent tumor resection. The primary outcome measure was determination of the maximum tolerated dose (MTD). Secondary outcome measures included overall survival (OS), progression-free survival (PFS), and radiographic correlation. RESULTS: A total of 10 patients have completed treatment with infusion doses of carboplatin of 1μg, 2μg, and 4μg. The total planned volume of infusion was 54mL for each patient. All patients had previously received surgery and chemoradiation. Histology at treatment include GBM (n = 9) and anaplastic oligodendroglioma (n = 1). Median KPS was 90 (range, 70 to 100) at time of treatment. Median PFS and OS were 2.1 and 9.6 months after completion of CED, respectively. A single adverse event possibly related to treatment was noted (generalized seizure). CONCLUSIONS: IC CED of carboplatin as a potential therapy for recurrent malignant glioma is feasible and safe at doses up to 4μg in 54mL over 72 hours. Further studies are needed to determine the maximum tolerated dose and potential efficacy.
BACKGROUND:Carboplatin is a potent cytoreductive agent for a variety of solid tumors. However, when delivered systemically, clinical efficacy for the treatment of high grade gliomas is poor due to limited penetration across the blood-brain barrier (BBB). Direct intracerebral (IC) convection-enhanced delivery (CED) of carboplatin has been used to bypass the BBB and successfully treat the F98 ratglioma. Based on these studies, we initiated a Phase I clinical trial. OBJECTIVE: This Phase I clinical trial was conducted to establish the maximum tolerated dose and define the toxicity profile of carboplatin delivered intracerebrally via convection enhanced delivery (CED) for patients with high grade glial neoplasms. METHODS: Cohorts of 3 patients with recurrent WHO grade III or IV gliomas were treated with escalating doses of CED carboplatin (1-4 μg in 54mL over 72 hours) delivered via catheters placed at the time of recurrent tumor resection. The primary outcome measure was determination of the maximum tolerated dose (MTD). Secondary outcome measures included overall survival (OS), progression-free survival (PFS), and radiographic correlation. RESULTS: A total of 10 patients have completed treatment with infusion doses of carboplatin of 1μg, 2μg, and 4μg. The total planned volume of infusion was 54mL for each patient. All patients had previously received surgery and chemoradiation. Histology at treatment include GBM (n = 9) and anaplastic oligodendroglioma (n = 1). Median KPS was 90 (range, 70 to 100) at time of treatment. Median PFS and OS were 2.1 and 9.6 months after completion of CED, respectively. A single adverse event possibly related to treatment was noted (generalized seizure). CONCLUSIONS: IC CED of carboplatin as a potential therapy for recurrent malignant glioma is feasible and safe at doses up to 4μg in 54mL over 72 hours. Further studies are needed to determine the maximum tolerated dose and potential efficacy.
Authors: Weilian Yang; Tianyao Huo; Rolf F Barth; Nilendu Gupta; Michael Weldon; John C Grecula; Brian D Ross; Benjamin A Hoff; Ting-Chao Chou; Julia Rousseau; Hélène Elleaume Journal: J Neurooncol Date: 2010-06-25 Impact factor: 4.130
Authors: Leslie L Muldoon; Carole Soussain; Kristoph Jahnke; Conrad Johanson; Tali Siegal; Quentin R Smith; Walter A Hall; Kullervo Hynynen; Peter D Senter; David M Peereboom; Edward A Neuwelt Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544
Authors: R J Strege; Y J Liu; A Kiely; R M Johnson; E M Gillis; P Storm; B S Carson; G I Jallo; M Guarnieri Journal: J Neurooncol Date: 2004-05 Impact factor: 4.130
Authors: Neil U Barua; Kirsten Hopkins; Max Woolley; Stephen O'Sullivan; Rob Harrison; Richard J Edwards; Alison S Bienemann; Marcella J Wyatt; Azeem Arshad; Steven S Gill Journal: Drug Deliv Date: 2014-05-02 Impact factor: 6.419
Authors: Chibueze D Nwagwu; Amanda V Immidisetti; Michael Y Jiang; Oluwasegun Adeagbo; David C Adamson; Anne-Marie Carbonell Journal: Pharmaceutics Date: 2021-04-15 Impact factor: 6.321